European regulators investigating reports of suicide risk in patients taking Novo Nordisk meds for weight loss

The Eu­ro­pean Med­i­cines Agency is look­ing in­to sui­ci­dal and self-harm ideation in three weight loss pa­tients who used No­vo Nordisk’s semaglu­tide or li­raglu­tide med­i­cines.

The case re­ports were flagged by mem­ber agency Ice­landic Med­i­cines Agency. The EMA’s safe­ty com­mit­tee, the Phar­ma­covig­i­lance Risk As­sess­ment Com­mit­tee (PRAC), is now in­ves­ti­gat­ing.

“The case re­ports in­clud­ed two cas­es of sui­ci­dal thoughts, one fol­low­ing the use of Sax­en­da and one af­ter Ozem­pic. One ad­di­tion­al case re­port­ed thoughts of self-in­jury with Sax­en­da,” the EMA said via email to End­points News.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN